Medpace Holdings, Inc. (MEDP) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
↓
21.21
↓-23% vs avg
5yr avg: 27.40
30Y Low13.0·High35.8
P/FCF
↓
17.87
↓-27% vs avg
5yr avg: 24.56
30Y Low13.9·High34.9
P/B Ratio
↑
27.45
↑+47% vs avg
5yr avg: 18.72
30Y Low2.1·High36.1
ROE
↑
70.2%
↓+43% vs avg
5yr avg: 49.2%
30Y Low-4%·High70%
Debt/EBITDA
↓
0.44
↓-6% vs avg
5yr avg: 0.47
30Y Low0.3·High5.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MEDP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Medpace Holdings, Inc. trades at 27.9x earnings, 19% below its 5-year average of 34.4x, sitting at the 20th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 26%. On a free-cash-flow basis, the stock trades at 17.9x P/FCF, 27% below the 5-year average of 24.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12.2B | $16.6B | $10.6B | $9.8B | $7.2B | $8.2B | $5.2B | $3.2B | $2.0B | $1.4B | $1.3B |
| Enterprise Value | $11.9B | $16.3B | $10.1B | $9.7B | $7.3B | $7.9B | $5.1B | $3.1B | $2.0B | $1.6B | $1.4B |
| P/E Ratio → | 27.93 | 36.76 | 26.30 | 34.52 | 29.18 | 45.25 | 36.25 | 31.48 | 26.87 | 37.00 | 97.49 |
| P/S Ratio | 4.82 | 6.55 | 5.04 | 5.18 | 4.90 | 7.18 | 5.67 | 3.67 | 2.77 | 3.31 | 3.11 |
| P/B Ratio | 27.45 | 36.12 | 12.88 | 17.46 | 18.51 | 8.61 | 6.51 | 4.35 | 3.31 | 2.87 | 2.15 |
| P/FCF | 17.87 | 24.32 | 18.59 | 24.60 | 20.37 | 34.90 | 23.09 | 17.17 | 13.90 | 16.98 | 16.76 |
| P/OCF | 17.09 | 23.25 | 17.47 | 22.52 | 18.43 | 31.16 | 20.29 | 15.65 | 12.48 | 14.83 | 14.28 |
P/E links to full P/E history page with 30-year chart
MEDP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Medpace Holdings, Inc.'s enterprise value stands at 21.2x EBITDA, 23% below its 5-year average of 27.4x. The Healthcare sector median is 14.1x, placing the stock at a 50% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.46 | 4.80 | 5.12 | 5.01 | 6.89 | 5.49 | 3.57 | 2.85 | 3.76 | 3.41 |
| EV / EBITDA | 21.21 | 29.02 | 21.25 | 26.59 | 24.29 | 35.83 | 27.26 | 20.42 | 14.37 | 14.73 | 12.99 |
| EV / EBIT | 22.32 | 30.12 | 22.64 | 28.67 | 26.24 | 39.64 | 30.45 | 24.14 | 19.89 | 25.42 | 34.76 |
| EV / FCF | — | 23.96 | 17.68 | 24.34 | 20.82 | 33.50 | 22.37 | 16.70 | 14.30 | 19.27 | 18.38 |
MEDP Profitability
Margins and return-on-capital ratios measuring operating efficiency
Medpace Holdings, Inc. earns an operating margin of 21.1%. Operating margins have expanded from 17.9% to 21.1% over the past 3 years, signaling improving operational efficiency. Return on equity of 70.2% is exceptionally high. ROIC of 154.9% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.1% | 30.1% | 31.1% | 27.8% | 29.6% | 28.7% | 30.1% | 28.5% | 30.6% | 40.1% | 40.8% |
| Operating Margin | 21.1% | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% | 18.0% | 14.8% | 14.3% | 14.9% | 12.5% |
| Net Profit Margin | 17.8% | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | 15.7% | 11.7% | 10.4% | 9.0% | 3.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 70.2% | 70.2% | 58.4% | 59.8% | 36.6% | 20.7% | 19.0% | 15.3% | 13.4% | 7.0% | 2.6% |
| ROA | 22.1% | 22.1% | 21.5% | 18.8% | 16.3% | 11.9% | 11.5% | 9.5% | 7.6% | 4.1% | 1.4% |
| ROIC | 154.9% | 154.9% | 88.1% | 50.4% | 35.7% | 23.5% | 19.5% | 14.8% | 11.3% | 6.8% | 5.2% |
| ROCE | 65.7% | 65.7% | 51.7% | 52.6% | 33.7% | 19.3% | 19.1% | 16.8% | 13.8% | 8.3% | 6.3% |
MEDP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Medpace Holdings, Inc. carries a Debt/EBITDA ratio of 0.4x, which is very conservative (86% below the sector average of 3.3x). The company holds a net cash position — cash of $497M exceeds total debt of $250M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.55 | 0.55 | 0.18 | 0.25 | 0.49 | 0.14 | 0.14 | 0.06 | 0.14 | 0.44 | 0.27 |
| Debt / EBITDA | 0.44 | 0.44 | 0.31 | 0.39 | 0.63 | 0.60 | 0.62 | 0.30 | 0.57 | 1.99 | 1.48 |
| Net Debt / Equity | — | -0.54 | -0.63 | -0.18 | 0.42 | -0.35 | -0.20 | -0.12 | 0.10 | 0.39 | 0.21 |
| Net Debt / EBITDA | -0.44 | -0.44 | -1.09 | -0.28 | 0.53 | -1.50 | -0.87 | -0.58 | 0.40 | 1.75 | 1.14 |
| Debt / FCF | — | -0.36 | -0.91 | -0.26 | 0.46 | -1.41 | -0.72 | -0.47 | 0.40 | 2.29 | 1.62 |
| Interest Coverage | — | — | — | 690.22 | 95.94 | 1891.57 | — | 81.16 | 12.39 | 8.53 | 2.13 |
Net cash position: cash ($497M) exceeds total debt ($250M)
MEDP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.74x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.64x to 0.74x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.74 | 0.74 | 0.93 | 0.64 | 0.42 | 1.24 | 1.08 | 0.92 | 0.69 | 0.67 | 0.79 |
| Quick Ratio | 0.74 | 0.74 | 0.93 | 0.64 | 0.42 | 1.24 | 1.08 | 0.92 | 0.69 | 0.67 | 0.79 |
| Cash Ratio | 0.37 | 0.37 | 0.61 | 0.27 | 0.04 | 0.83 | 0.63 | 0.38 | 0.09 | 0.14 | 0.22 |
| Asset Turnover | — | 1.28 | 1.00 | 1.14 | 1.08 | 0.69 | 0.67 | 0.75 | 0.73 | 0.46 | 0.43 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 69865.57 | 37351.86 | 809.97 |
| Days Sales Outstanding | — | 58.00 | 51.30 | 57.75 | 63.35 | 59.57 | 63.45 | 65.99 | 69.13 | 69.53 | 69.06 |
MEDP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Medpace Holdings, Inc. returns 7.5% to shareholders annually primarily through share buybacks. The earnings yield of 3.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.6% | 2.7% | 3.8% | 2.9% | 3.4% | 2.2% | 2.8% | 3.2% | 3.7% | 2.7% | 1.0% |
| FCF Yield | 5.6% | 4.1% | 5.4% | 4.1% | 4.9% | 2.9% | 4.3% | 5.8% | 7.2% | 5.9% | 6.0% |
| Buyback Yield | 7.5% | 5.5% | 1.6% | 1.5% | 11.9% | 0.8% | 1.9% | 0.0% | 0.0% | 10.8% | 0.0% |
| Total Shareholder Yield | 7.5% | 5.5% | 1.6% | 1.5% | 11.9% | 0.8% | 1.9% | 0.0% | 0.0% | 10.8% | 0.0% |
| Shares Outstanding | — | $30M | $32M | $32M | $34M | $38M | $38M | $38M | $37M | $40M | $36M |
Peer Comparison
Compare MEDP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MEDPYou | $12B | 27.9 | 21.2 | 17.9 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 ICLR | $9B | 13.0 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 PRA | $1B | 24.8 | 19.5 | — | 39.4% | 6.6% | 4.0% | 3.2% | 5.1 |
 HIMS | $7B | 52.7 | 44.5 | 93.8 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 IQV | $30B | 22.5 | 12.9 | 14.6 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 TMO | $176B | 26.7 | 19.0 | 27.9 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $124B | 34.7 | 18.1 | 23.5 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BIO | $7B | 9.3 | 16.8 | 18.7 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 VEEV | $27B | 30.8 | 28.2 | 19.2 | 75.5% | 28.7% | 13.9% | 12.9% | 0.1 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
Full MEDP Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See MEDP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MEDP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MEDP vs ICLR
Side-by-side business, growth, and profitability comparison vs ICON Public Limited Company.
Start ComparisonMEDP — Frequently Asked Questions
Quick answers to the most common questions about buying MEDP stock.
What is Medpace Holdings, Inc.'s P/E ratio?
Medpace Holdings, Inc.'s current P/E ratio is 27.9x. The historical average is 40.1x. This places it at the 20th percentile of its historical range.
What is Medpace Holdings, Inc.'s EV/EBITDA?
Medpace Holdings, Inc.'s current EV/EBITDA is 21.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 22.7x.
What is Medpace Holdings, Inc.'s ROE?
Medpace Holdings, Inc.'s return on equity (ROE) is 70.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 24.8%.
Is MEDP stock overvalued?
Based on historical data, Medpace Holdings, Inc. is trading at a P/E of 27.9x. This is at the 20th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Medpace Holdings, Inc.'s profit margins?
Medpace Holdings, Inc. has 30.1% gross margin and 21.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Medpace Holdings, Inc. have?
Medpace Holdings, Inc.'s Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.